Mel and the team have a fantastic show planned for you tonight. Our expert guests will give you the latest updates on therapeutics, pediatric syndrome, cardiac manifestations, ICU care, and reports from faculty and friends on the front lines around the world. We will also conduct a critical review of Remdesivir, discuss who and when to anticoagulate, and thoroughly review what we know to date about this disease and what still remains unknown.
HIGHLIGHTS FROM THIS PROGRAM:
00:00 Intro
04:45 COVID-19 - What We (think) We Know, What We Don’t
10:50 Words that Stuart Uses That You Don't Know
11:42 CorePendium Chapter Updates
14:57 Reports from the Front Line
26:25 Therapeutics Update
46:12 Questions from the Chat Room
53:35 Pediatric Update
01:11:23 Who Should We Anticoagulate?
01:18:30 Contact Tracing
01:22:40 Questions from the Chat Room
01:23:20 Shabam -Thinking in Probabilities
01:27:31 Farewell
Link to Shabam - Thinking in Probabilities: https://youtu.be/REizWkvaWrc
Peter B., M.D. - June 4, 2020 2:49 PM
Are you aware of recent article by Dr. Harvey Risch (Yale Epidemiologist) about use of hydroxychloroquine and azithromycin or doxycycline on covid-19 outpatients with obesity and co-morbidities? Would be interested in your take on his article.
Pete Baye, MD
Mel H. - June 5, 2020 10:18 AM
This is the article: https://kopernio.com/viewer?doi=10.1093%2Faje%2Fkwaa093&token=WzYyNjE1OSwiMTAuMTA5My9hamUva3dhYTA5MyJd.wKH_IxTBRYT8MbKwb6j3mN4O6p4
Frankly I find his reasoning pretty weak and if we have learned anything it is that we need real data. The data he quotes is pretty crappy. We should soon get the HERO study of 15,000 health care workers randomaized, blinded. placebo controlled, then we will have something to talk about.
Mike H., MD - June 28, 2020 3:58 AM
Thank you for your kind words in the beginning Mel!